RxSight, Inc. (RXST)

The investment case for RxSight is currently broken by a perfect storm of deteriorating fundamentals and overwhelming speculative pessimism. The company is trapped in a multi-year value trap, having lost nearly 40% of its value over the last four years despite a massive spike in 2023, followed by a catastrophic collapse in 2025 where shares shed 85%. Fundamentally, the business is bleeding cash with negative operating margins of roughly 41%, negative free cash flow, and a return on equity of -17%. While the balance sheet remains technically intact with a current ratio of 4.07, the inability to generate profit or cash flow suggests the core commercial model is failing. The short-term outlook is bleak, reinforced by the options market which is screaming 'sell' with massive put positioning at key resistance levels like $5.00. The recent price action confirms this weakness, with the stock trading well below its 50-day and 200-day moving averages, indicating persistent selling pressure. There is no dividend to provide income, and the lack of analyst coverage ('none') combined with a negative forward P/E signals that the market has effectively written off the company's near-term prospects. Until there is clear evidence of a turnaround in profitability or a successful monetization of its pipeline, this remains a high-risk speculative holding with no clear path to recovery.